Traditional NSAIDs Do Not Raise Cardiovascular Risk – JAMA Review
This article was originally published in The Tan Sheet
Executive Summary
The nonselective NSAIDs naproxen and ibuprofen appear neither to increase nor decrease the risk of cardiovascular events, according to a Journal of the American Medical Association data review published online Sept. 12
You may also be interested in...
ADAPT Data Linking Naproxen To Heart Risk Is “Not Reliable” – Nissen
The premature halting of the ADAPT trial and subsequent safety concerns for naproxen were "inappropriate and reflected faulty logic," according to Cleveland Clinic cardiologist Steven Nissen, MD
Naproxen Fares Better Than Ibuprofen In Cardiovascular-Risk Data
Traditional non-selective NSAIDs, with the exception of naproxen, carry similar cardiovascular risk to COX-2 inhibitors, according to results of a study released by the Agency for Healthcare Research & Quality (AHRQ) Sept. 25
Merck Vioxx Detailing Should Have Addressed VIGOR Risks – FDA’s Jenkins
Merck should have included risk findings from the VIGOR study when promoting Vioxx to physicians before the data was added to labeling, FDA Office of New Drugs Director John Jenkins told a congressional hearing May 5